

35<sup>th</sup> World congress on **Pharmacology**


38<sup>th</sup> International Conference on

**Advanced Nanotechnology**

12<sup>th</sup> European Chemistry Congress

August 01-02, 2022

WEBINAR



## Posters

## **Combination of photothermal, prodrug and tumor cell camouflage technologies for triple-negative breast cancer treatment**

**Xiaodong Ma**

University of Turku and Åbo Akademi University, Finland

Traditional medicine has been widely used. Triple-Negative Breast Cancer (TNBC) remains the most challenging breast cancer subtype. In the presented work, we have combined several emerging technologies to build up a nanoplatform for TNBC treatment: photothermal therapy, prodrug design and tumor cell camouflage formulation. First, we synthesized a paclitaxel (PTX) based prodrug PTX-SS, and then conjugated it to the surface of gold nanorod (Au NR) @ mesoporous silica (MSN) core-shell nanoparticles (Au@MSN-NH<sub>2</sub> NPs). Subsequently, doxorubicin (DOX) was loaded into the Au@PTXSS-MSN NPs and further coated with cell membranes isolated from MDA-MB-231 cells to form cell camouflaged Au@PTXSS-MSN/DOX@CM NPs. The Au@PTXSS-MSN/DOX@CM NPs exhibited very good DOX loading capacity and the prodrug strategy enabled the precise adjustability of PTX-SS loading to achieve the optimized ratio between PTX and DOX to maximize the synergistic effect of these two drugs, as well as enabled GSH-responsive intracellular drug release. More interestingly, the cell membrane coating not only protected the drug from premature release, but also significantly improved the targeting ability of NPs to breast cancer MDA-MB-231 cells. The NPs also showed good photothermal responsiveness with clear improvement in inhibiting MDA-MB-231 cell proliferation under laser irradiation. The in vivo studies further confirmed the effectiveness of Au@PTXSS-MSN/DOX@CM NPs on TNBC tumor inhibition in 4T1 cell grafted tumor mice model.

**Importance of Research:** Triple-Negative Breast Cancer (TNBC) is the most aggressive breast cancer that is accompanied by poor prognosis and high rate of recurrence and metastasis. The using of targeted anti-cancer drugs (such as Herceptin, Lapatinib and Pertuzumab) has dramatically improved the prognosis of breast cancer; however, TNBC still lacks effective therapeutic drugs due to the lack expression of hormone receptors (include estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2), which are widely used for breast cancer targeting therapy. Cell camouflage technologies that utilize cancer cell originating cell membranes to hidden the drug carrier nanoparticles (NPs), have been found to be a good strategy for targeted cancer therapy owing to the extensive homology of the proteins and antigens between the cell membrane and cancer cells, as well as the homing ability of cancer cells. In summary, we have developed a new photothermal and GSH responsive NP with cell camouflage for targeted TNBC therapy. The Au NRs were embedded into the Au@PTXSS-MSN/DOX@CM with photothermal therapy activity, while the porous shell structure formed by MSN realized the high drug loading capacity to load the hydrophilic DOX. The prodrug technology enabled the PTX prodrug to have a GSH responsive linker and a conjugation site for conjugating onto the MSN. The coated cell membrane originating from tumor cells can protect the drugs from premature releasing and greatly improved the tumor targeting efficiency. Au@PTXSS-MSN/DOX@CM NPs have been

confirmed to have good tumor cell targeting and synergistic anti-tumor effects at the cellular level. In addition, the Au@PTXSS-MSN/DOX@CM NPs also generated significant anti-tumor activity in vivo, as well as further improve the on-site drug release, for targeted TNBC therapy.

### Recent Publications

1. G. Bianchini, J. M. Balko, I. A. Mayer, M. E. Sanders, L. Gianni, *NAT REV CLIN ONCOL*. 2016, 13, 674.
2. L. Yin, J. J. Duan, X. W. Bian, S. C. Yu, *Breast Cancer Res*. 2020, 22, 61.
3. D. Nie, Z. Dai, J. Li, Y. Yang, Z. Xi, J. Wang, W. Zhang, K. Qian, S. Guo, C. Zhu, R. Wang, Y. Li, M. Yu, X. Zhang, X. Shi, Y. Gan, *Nano lett*. 2020, 20, 936.
4. J. Rautio, H. Kumpulainen, T. Heimbach, R. Oliyai, D. Oh, T. Jarvinen, J. Savolainen, *Nat Rev Drug Discov*. 2008, 7, 255; b) J. Rautio, N. A. Meanwell, L. Di, M. J. Hageman, *Nat Rev Drug Discov*. 2018, 17, 559.
5. N. Hattori, M. Sako, K. Kimura, N. Iida, H. Takeshima, Y. Nakata, Y. Kono, T. Ushijima, *Clin Epigenetics*. 2019, 11, 111.
6. G. Liang, Y. Zhu, D. J. Ali, T. Tian, H. Xu, K. Si, B. Sun, B. Chen, Z. Xiao, *J Nanobiotechnology*. 2020, 18, 10.
7. S. Joshi, M. T. Hussain, C. B. Roces, G. Anderluzzi, E. Kastner, S. Salmaso, D. J. Kirby, Y. Perrie, *Int. J. Pharm*. 2016, 514, 160.
8. J. Yan, X. Xu, J. Zhou, C. Liu, L. Zhang, D. Wang, F. Yang, H. Zhang, *Acs Appl Bio Mater* 2020, 3, 1216.

### Biography

Xiaodong Ma began to study for a PhD at Abo Akademi University in 2020. His research includes functional biological nanomaterials, with an emphasis on prodrug synthesis, nanocarrier synthesis and related biological applications. During his research, Dr. Ma constructed several nano drug delivery vehicles based on stimulation-responsive mesoporous silicon dioxide nanoparticles (MSNs) and prodrug nanoparticles. By utilizing the stimulation characteristics of tumor microenvironment and external light source, Dr. Ma realized the controlled release of antitumor drugs, immunosuppressants and bioactive macromolecules to enhance the tumor treatment effect, paving the way for the application of prodrugs in the biomedical field.

**Received:** July 11, 2022; **Accepted:** July 14, 2022; **Published:** August 01, 2022

35<sup>th</sup> World congress on **Pharmacology**


38<sup>th</sup> International Conference on

**Advanced Nanotechnology**

12<sup>th</sup> European Chemistry Congress

August 01-02, 2022

WEBINAR



**Accepted Abstracts**

## **Biosynthesis of selenium nanoparticles by aspergillus flavus and candida albicans for antifungal applications**

**Mohammadali Ghanbarinazhagh**

Department of Medical Parasitology and Mycology, Ghaem hospital, Mashhad University of Medical Sciences, Mashhad, Iran

**B**iosynthesis of nanoparticles can replace the available chemical and physical methods by offering new procedures as green syntheses that have proved to be simple, biocompatible, safe, and cost-effective. Recently, antifungal resistance has been reported against different species of *Aspergillus* and *Candida* opportunistic fungi. Selenium nanoparticles (Se-NPs) were biosynthesized using standard strains of *Aspergillus flavus* and *Candida albicans*. The presence of nanoparticles was confirmed by UV-Vis, FT-IR, FESEM, EDX, XRD, and Zeta potential. Common fungal strains were cultured in Sabouraud dextrose agar medium to perform the sensitivity test based on the minimum inhibitory concentration (MIC) method in duplicate. The utilization of Se-NPs at concentrations of 1, 0.5, and 0.25 µg/ ml or in some strains even more minor than 0.125 µg/ ml resulted in zero growth of fungal agents. However, antifungal drugs inhibited their growth at concentrations of 2, 4, 8, 16, and 64 µg/ ml itraconazole (ITC). Also, MIC breakpoints for amphotericin B (AMB) and anidulafungin (AFG) were 2 µg/ ml for defining resistance in some isolates. Based on the obtained results, biological NPs produced by Aspergillus and *Candida* at different concentrations exhibited favorable inhibitory effects on the growth of fungal strains.

**Keywords:** Biosynthesis; Selenium nanoparticles; Antifungal resistance; MIC; *Aspergillus*; *Candida*

## Light-emitting diodes: As external stimulus for plant-mediated biosynthesis and biological activities of silver nanoparticles

Sumaira Anjum

Department of Biotechnology, Kinnaird College for Women, Pakistan.

The trend of using biological entities particularly plant extracts for nanoparticles (NPs) synthesis has expedited in recent years due to environmental safety, cost effectiveness, simplicity and sustainability of green route. Moreover, the morphology of NPs could be fine-tuned by applying abiotic factors such as LEDs which enhance the bio-reduction of precursor salt and excites phytochemicals during the green synthesis. Given this, in present study the green synthesis of AgNPs was carried out using by dalbergia sissoo leaves extract under the illumination of red, green, blue, yellow and white LEDs. Phytochemical analysis revealed that D. session was enriched with phenolic ( $23.6 \pm 0.76$  mg GAE/g DW) as well as flavonoids content ( $1.65 \pm 0.01$  mg QE/g DW) which attributed to high FRSA ( $80.84 \pm 0.87$  %). The phytochemical profile reflected upon the effective synthesis of AgNPs as alcohols and phenols were mainly involved in capping and bio-reduction revealed from FTIR analysis. Moreover, XRD analysis showed face center cubic crystalline nature of AgNPs with interesting finding that LEDs helped in reducing the size of AgNPs significantly. Y-DS-AgNPs (34.63 nm) being smallest in size as compared to control (87.35 nm). LEDs not only reduced the size of AgNPs but SEM analysis showed synthesis of non-agglomerated differently shaped AgNPs including spherical, triangular, hexagonal as compared to mixed shape control AgNPs. Theses green biocompatible AgNPs showed extraordinary therapeutic potential specially B-DS-AgNPs resulted in highest anti-oxidant (FRAP  $485.6 \pm 9.6$   $\mu$ M TEAC; CUPRAC  $588.1 \pm 8.4$   $\mu$ M TEAC; ABTS  $323.4 \pm 10.4$   $\mu$ M and ORAC  $469.2 \pm 11.3$   $\mu$ M TEAC), anti-glycation ( $63.3 \pm 2$  % and  $33.1 \pm 3$  % inhibition of vesperlysine-like AGEs and pentosidine-like AGEs) as well as anti-bacterial activities. While Y-DS-AgNPs effectively inhibited HepG2 cells growth (cell viability  $26.01 \pm 1.56$  %) by inducing intracellular ROS/RNS generation ( $3807.62 \pm 236.63$  relative DHR-123 fluorescence), disrupting mitochondrial membrane potential ( $1839.29 \pm 162.45$  RFU) via caspase-3 gene activation ( $419.15 \pm 106.51$  log 2-fold change) and enhanced caspase-3/7 activity ( $137.26 \pm 41.13$  RFU/mg protein). Lastly, these NPs showed mild toxicity towards brine shrimp and caused moderate hRBCs hemolysis, showing their biosafety nature which can be enhanced at lower concentrations. Here we conclude that external factors such as LEDs are effective in controlling the morphology of AgNPs which reflects upon their enhanced biological efficacy.